Overcoming Trastuzumab-Pertuzumab Resistance and Optimizing Sequential Anti-HER2 Therapy in HER2-Positive Metastatic Breast Cancer.

Cancers (Basel) · 2026 · PMC13024778 · PMID 41899536

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a prespecified exploratory analysis of the CD16A-158 polymorphism (V, high-affinity; F, low-affinity), patients with the CD16A-158FF genotype showed a trend toward improved OS with margetuximab compared with trastuzumab (median, 23.6 vs. 19.2 months; HR, 0.72; 95% CI, 0.52–1.00).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.